Definium Therapeutics (DFTX) Insider Adsett Buys 3,555 Shares

On June 11, 2026, Roger Adsett, an insider at Definium Therapeutics, Inc. (NasdaqGS: DFTX), acquired 3,555 shares of the company at no cost per share. This insider purchase suggests a degree of confidence in the company's future prospects.

Insider Buying and Selling at Definium Therapeutics, Inc.

Roger Adsett's recent purchase of 3,555 shares on June 11, 2026, wasn't the only insider transaction at Definium Therapeutics. Andreas Krebs also bought 19,188 shares, and Suzanne Louise Bruhn acquired 4,666 shares on the same day. All transactions were conducted without a specific plan, indicating voluntary insider confidence.

Other Institutional Activity in Definium Therapeutics

BlackRock, Inc. significantly expanded its position in Definium Therapeutics by adding 8,480,230 shares, bringing its total to 8,480,230 shares valued at about $160.3 million. Janus Henderson Group PLC also increased its holdings, ending with 3,556,041 shares worth approximately $67.2 million. Meanwhile, Driehaus Capital Management LLC reduced its stake by 625,313 shares, holding 5,911,889 shares valued at around $111.7 million.

Definium Therapeutics, Inc. Stock Down 36.2%

Shares of Definium Therapeutics, Inc. (NasdaqGS: DFTX) are trading near $24.75. The company has a market cap of approximately $2.7 billion. Although it isn't currently profitable, with a forward P/E of -15.66, it has a high beta of 2.378, indicating potential volatility. The stock's 52-week range is between $6.35 and $26.25, with moving averages of $22.33 over 50 days and $15.99 over 200 days. The company's strong liquidity is reflected in a current ratio of 4.692 and a quick ratio of 4.604.

Analysts Set New Price Targets

On May 8, 2026, Piper Sandler maintained a 'buy' rating on Definium Therapeutics with a price target of $48. Similarly, HC Wainwright & Co. continues to see upside potential, maintaining a 'buy' rating with a target of $70. The consensus among analysts is a 'strong buy', with an average price target of $39.87 from 15 analyst opinions.

About Definium Therapeutics

Definium Therapeutics, Inc. is a biotechnology company based in New York, focusing on developing treatments for brain health disorders. Its leading candidates include DT120, in phase 3 trials for anxiety and depressive disorders, and DT402, in phase 2 trials for autism. Led by CEO Robert Barrow, the company employs 105 people and continues to innovate in the healthcare sector.

Bottom Line

Roger Adsett's insider purchase of Definium Therapeutics shares highlights his confidence in the company's future. While the company is not yet profitable, its innovative pipeline and strong liquidity position it well in the biotech field. Investors should note that insider transactions and analyst ratings often provide insight into market sentiment, but they are one piece of the broader investment puzzle.